SAN

77.5

+0.82%↑

ARGX

701.2

+1.3%↑

SHL.DE

34.5

+1.08%↑

FRE

40.06

+0.07%↑

PHIA

23.17

+1.44%↑

SAN

77.5

+0.82%↑

ARGX

701.2

+1.3%↑

SHL.DE

34.5

+1.08%↑

FRE

40.06

+0.07%↑

PHIA

23.17

+1.44%↑

SAN

77.5

+0.82%↑

ARGX

701.2

+1.3%↑

SHL.DE

34.5

+1.08%↑

FRE

40.06

+0.07%↑

PHIA

23.17

+1.44%↑

SAN

77.5

+0.82%↑

ARGX

701.2

+1.3%↑

SHL.DE

34.5

+1.08%↑

FRE

40.06

+0.07%↑

PHIA

23.17

+1.44%↑

SAN

77.5

+0.82%↑

ARGX

701.2

+1.3%↑

SHL.DE

34.5

+1.08%↑

FRE

40.06

+0.07%↑

PHIA

23.17

+1.44%↑

Accueil・Liste d'Actions・Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi SA

Ouvert

SecteurSoins de santé

59.9 0.84

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

59.25

Max

Chiffres clés
By Trading Economics
Revenu	-33M 9.5M
Ventes	-66M 152M
P/E Moyenne du Secteur	24.576 49.701
BPA	0.185
Marge bénéficiaire	6.216
Employés	1,950
EBITDA	-45M 18M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+26.46% upside

Dividendes
By Dow Jones
Prochains Résultats	23 juil. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-1.1B 3B
Ouverture précédente	59.06
Clôture précédente	59.9

Sentiment de l'Actualité

By Acuity

50%

159 / 345 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

51.1 / N/A Support & Résistance

Laboratorios Farmaceuticos Rovi SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

20 mai 2026, 23:31 UTC

Actions en Tendance

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20 mai 2026, 22:52 UTC

Principaux Mouvements du Marché

Osisko Shares Fall on Planned Convertible Notes Offering

20 mai 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20 mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20 mai 2026, 23:44 UTC

Résultats

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20 mai 2026, 23:35 UTC

Market Talk

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20 mai 2026, 23:30 UTC

Market Talk

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20 mai 2026, 23:17 UTC

Market Talk

Global Equities Roundup: Market Talk

20 mai 2026, 23:17 UTC

Market Talk

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20 mai 2026, 23:15 UTC

Market Talk

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20 mai 2026, 23:14 UTC

Résultats

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20 mai 2026, 23:02 UTC

Market Talk

KMD Brands Faces Two Testing Hurdles -- Market Talk

20 mai 2026, 22:57 UTC

Market Talk

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20 mai 2026, 22:57 UTC

Market Talk

Global Energy Roundup: Market Talk

20 mai 2026, 22:57 UTC

Market Talk

Global Equities Roundup: Market Talk

20 mai 2026, 22:51 UTC

Market Talk

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20 mai 2026, 22:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20 mai 2026, 22:27 UTC

Market Talk

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20 mai 2026, 22:14 UTC

Market Talk

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20 mai 2026, 22:10 UTC

Résultats

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20 mai 2026, 22:00 UTC

Résultats

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20 mai 2026, 21:38 UTC

Résultats

Acquisitions, Fusions, Rachats

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20 mai 2026, 21:27 UTC

Résultats

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20 mai 2026, 21:20 UTC

Résultats

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20 mai 2026, 21:19 UTC

Résultats

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20 mai 2026, 21:18 UTC

Résultats

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20 mai 2026, 21:17 UTC

Résultats

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20 mai 2026, 21:17 UTC

Résultats

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20 mai 2026, 21:17 UTC

Résultats

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20 mai 2026, 21:16 UTC

Résultats

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Comparaison

Variation de prix

Laboratorios Farmaceuticos Rovi SA prévision

Objectif de Prix

By TipRanks

26.46% hausse

Prévisions sur 12 Mois

Moyen 73.6 EUR 26.46%

Haut 83 EUR

Bas 64.2 EUR

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

Achat

Maintien

Vente

Basé sur 2 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

51.1 / N/ASupport & Résistance

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

159 / 345Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.